Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says

Executive Summary

Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12

You may also be interested in...



Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite

The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs

Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite

The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs

Merck Halts Gardasil Lobbying Efforts Following Discussions With ACIP, AAP

Merck decided to halt lobbying efforts for state legislation requiring vaccination with its human papilloma virus vaccine Gardasil for school entry following discussions with third party stakeholders, including CDC's Advisory Committee on Immunization Practices and the American Academy of Pediatrics, the company said

Related Content

UsernamePublicRestriction

Register

PS047865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel